Key Business Developments Financial Results for Quarter and Year Ended December ... Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to ...

During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s quarter and fiscal ... Legend is building an end-to-end cell therapy company by expanding ...

CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full ... Centered in the US, Legend is building an end-to-end cell therapy company by expanding ...

During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s quarter and fiscal year performance. Investors and other interested parties may join the live ...